TuHURA Biosciences (HURA) vs Minerva Neurosciences (NERV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Minerva Neurosciences (NERV) has outperformed TuHURA Biosciences (HURA) over the past year, losing 5.6% versus a loss of 26.7%. Over five years, NERV leads with a -76.9% price change compared with -99.9% for HURA. Minerva Neurosciences is the larger company by market cap ($112.2 million vs $112.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HURA | NERV |
|---|---|---|
| Share price | $1.76 | $2.35 |
| Market cap | $112.16M | $112.21M |
| 1-day change | -3.83% | -2.89% |
| YTD return | +132.50% | -41.54% |
| 1-year return | -26.67% | -5.62% |
| 5-year return | -99.89% | -76.87% |
| EPS (TTM) | $-0.54 | $-36.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | — |
| Net income (latest FY) | $-30.05M | $-293.42M |
| 52-week high | $3.43 | $12.46 |
| 52-week low | $0.41 | $2.28 |
| Distance from 52-week high | -48.69% | -81.14% |
| Analyst consensus | none | none |
| Avg. price target upside | +356.82% | +339.57% |
| Average volume | 221.74K | 181.64K |
| Shares outstanding | 63.73M | 47.75M |
| Employees | 22 | 7 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NERV has outperformed HURA by 21.0 percentage points over the past year.
About TuHURA Biosciences
HURA stock →TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors.
Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees
About Minerva Neurosciences
NERV stock →Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
HURA vs NERV FAQ
Which is bigger, TuHURA Biosciences or Minerva Neurosciences?
Minerva Neurosciences (NERV) is larger, with a market capitalization of $112.21M compared with $112.16M for TuHURA Biosciences (HURA).
Which stock has performed better over the past year, HURA or NERV?
NERV returned -5.62% over the past 12 months, compared with -26.67% for HURA (price return, excluding dividends). Past performance does not predict future results.
Are TuHURA Biosciences and Minerva Neurosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.